Parkinson's disease (PD) is one of the most commonly occurring neurodegenerative disorders, with lifetime incidence between 1 and 2% among people older than 65 years. ED is one of the more disabling and poorly addressed aspects of PD. The purpose of this study was to assess the efficacy and safety of sildenafil citrate in Parkinson-emergent ED. Sexual function of participants was assessed using responses to the 15-question International Index of Erectile Function (IIEF), Sexual Encounter Profile (SEP) diary questions 2 and 3, Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) questionnaire and a Global Efficacy Question 'Has the treatment you have been taking over the study period improved your erections?' This randomized, double-blind, placebocontrolled study, comprised a screening period of at least 1 month, a placebo-lead in period of 1 week and treatment period. Two hundred thirty-six patients entered the trial. These patients had mild-to-moderate PD (stages I-III Hoehn-Yahr) and were experiencing Parkinson-emergent neurogenic ED. They were randomized to receive 100 mg sildenafil on demand 1 h before sexual activity (group 1, n ¼ 118), or similar regimen of placebo (group 2, n ¼ 118). Patients were instructed to use at least 24 doses/attempts at home. At the end of the trial, differences between sildenafil and placebo groups were significant for the IIEF erectile function (EF) score (22.6 ± 4.6 vs 14.8 ± 4.2, P ¼ 0.01), for percent Global Efficacy Question 'Yes' responses (68.1±4.6 vs 12.2±3.2, P ¼ 0.001), for SEP2 'Yes' responses (68.1±4.2 vs 32.5±2.2, P ¼ 0.003), for SEP3 'Yes' responses (75.9±5.4 vs 33.5 ± 4.4, P ¼ 0.004) and for mean EDITS score (69.8 ± 4.2 vs 13.0 ± 2.7, P ¼ 0.004). A normal EF domain score (X26) at end point was achieved by 56.9 and 8.7% of the patients in the sildenafil and placebo groups, respectively (P ¼ 0.001). Sildenafil can be considered as an effective treatment in patients with Parkinson-emergent ED.
Introduction
Parkinson's disease (PD) is one of the most common progressive neurodegenerative disorders and is characterized clinically by four main symptoms: resting tremor, bradykinesia, rigidity and postural unsteadiness. The cumulative lifetime incidence of PD is above 1% and the prevalence is over 3%. 1 Symptoms of PD are caused by progressive loss of dopaminergic neurons in substantia nigra pars compacta. 2 With disease progression, the neurodegenerative nature of PD extends to affect the mesocortical, mesolimbic regions and autonomic systems. 3 Sexual dysfunction is a common compliant in PD patients. ED (68%) and sexual dissatisfaction (65%) are the most common sexual dysfunctions in men. 4 Several studies have demonstrated that ED is nearly twice as frequent in men with PD as in controls. 5 In general, ED affects men several years after a diagnosis of PD has been made. The risk of ED increases with advancing disease stage. ED is a manifestation of autonomic R E T R A C T E D failure in PD. 6 However, other contributory factors, such as age, associated comorbidities, personal relationships, loss of self-esteem, sleep disturbances, depression and drug therapy should also be considered. 7 Development of ED during the course of PD greatly affects patients' quality of life (QOL) and can take a serious psychological toll. 8 Despite the high prevalence and disabling effect of ED in PD, it is still one of the most poorly investigated aspects of the disease.
Sildenafil citrate is the first PDE5 inhibitor approved for the treatment of ED. Although sildenafil is effective for treating ED in men with various comorbid conditions, little is known about the effect of sildenafil on erectile function (EF) in men with PD. In the study by Raffaele et al., 9 33 depressed men with PD and ED received 50 mg of sildenafil 1 h before sexual activity. At the end of the study, 84.8% of patients reported improved erection. In another study, 10 men with idiopathic PD and ED were prescribed 50-100 mg sildenafil. There was statistically significant improvement in total Sexual Human Inventory for Males scores. 10 In the third study, 24 patients with parkinsonism and ED (12 with PD and 12 with multiple system atrophy) were recruited into a randomized, doubleblind, placebo-controlled, crossover study of sildenafil. 11 Sildenafil (50 mg) was efficacious in the treatment of ED.
The aim of our randomized clinical trial was to investigate the safety and efficacy of sildenafil citrate in non-depressed patients with Parkinsonemergent ED.
Materials and methods

Study population
Two hundred thirty-six patients with an established clinical diagnosis of PD (United Kingdom Parkinson Disease Brain Bank Criteria) 12 were consecutively selected among the population of 284 patients who were referred or addressed themselves to our Sexual Dysfunction Clinic, from September 2006 to March 2009. Participants were recruited through local advertisement. In advertisement, we suggested that only patients without a history of diagnosis of depression, diabetes mellitus, hypertension, cardiovascular disease and use of antidepressant medication will be recruited. All of the patients who were referred had above-mentioned primary inclusion criteria. About 90% of the participants were referred, and the remainder 10% addressed themselves. Concerning medical history, whenever useful, information given by the patient was checked with medical records. ED was defined as the inability to achieve and maintain an erection satisfactory for intercourse. The mean age of patients was 61.2±3.4 years, disease duration was 8.6±2.7 years and mean Hoehn-Yahr grade was 2.2 ± 0.4 (range 1-3). The severity of PD was measured according to the Hoehn-Yahr stages. 13 This is a five-stage scale that measures the clinical severity of PD, with stage I representing mild unilateral involvement and stage V representing severe wheelchair-bound/bedridden illness in which affected individual is totally dependent on caregivers. All subjects were receiving levodopa, with a mean daily dose of 376.4±182.2 mg. Those treated or co-treated with other anti-Parkinson medication were excluded. Patients had to have ED for at least 6 months and were involved in a stable sexual relationship with a female partner for X12 months. Patients were excluded if they met the Diagnostic and Statistical Manual, 4th edition criteria for a psychotic or affective disorder including depression.
14 Dementia was ruled out by using DSM-IV criteria and a cutoff score of 123 on the Dementia Rating Scale. 15 All of the participants were naïve for PDE5 inhibitors.
Eligible patients were fully informed of the aims and requirements of the trial, and all subjects gave informed consent for participation in the trial. The local Medical Ethic Committee approved the study. This study was performed in compliance with the International Conference on Harmonization and Good Clinical Practice Guidelines, 16 as consistent with the Declaration of Helsinki 2002 and applicable laws.
Inclusion criteria
Patients were eligible for inclusion in the study if they had neurogenic ED. All subjects met the following inclusion criteria: age 35-65 years; a diagnosis of idiopathic PD; possible sexual intercourse X1 per week; stable medication usage, defined as the lowest level of levodopa required to control motor symptoms for at least 6 weeks immediately before study entry; been responsive to dopamimetics for motor symptoms; Hoehn-Yahr stages I-III; experienced ED for at least 6 months; no other neurologic or psychiatric disorder and not having participated in a rehabilitation program in the previous 6 months.
Key exclusion criteria
Men were excluded from the study if they had other neurologic or psychiatric disorder; secondary parkinsonism and parkinsonian syndromes; a primary diagnosis of another sexual disorder such as premature ejaculation; vasculogenic, psychogenic and endocrinological causes of ED; serious relationship problems; significant hepatic or renal function impairment (hepatic enzymes 41.5 times the upper limit of normal and/or serum creatinine 41.8 mg per 100 ml); hypertension (4170/110 mm Hg),
hypotension (o90/50 mm Hg) or significant cardiovascular disease (unstable angina, coronary artery disease, myocardial infarction or myocardial revascularization).
Other key exclusion criteria were, prior use of any available PDE5 inhibitors (sildenafil, vardenafil and tadalafil); associated comorbid conditions, including diabetes mellitus, hyperlipidemia and Peyronie's disease; smokers of more than five cigarettes daily; taking drugs that could give rise to extrapyramidal signs and taking psychotropic medications, androgens, anti-androgens or 5a-reductase inhibitors.
Evaluations
Initial evaluations included a detailed medical and sexual history; physical examination, 12-lead electrocardiogram, review of medications, blood draw for clinical laboratory tests and completion of the Hoehn-Yahr Scale. To minimize the problem of response bias, all patients were seen with their wives, and interviewed separately about their sexual activity and patient's EF. Clinical laboratory tests included complete blood count, blood chemistry and serum levels of the following hormones: luteinizing hormone, follicle-stimulating hormone testosterone, thyroidstimulating hormone and prolactin. To be able to establish the diagnosis of vasculogenic, neurogenic and psychogenic ED, penile color duplex Doppler ultrasonography before and after intracavernosal injection with 20 mg prostaglandin E 1 , pudendal nerve conduction tests, impaired sensory-evoked potential studies and measurement of nocturnal penile tumescence by means of a Rigiscan device, were performed.
The hemodynamics of penile blood vessels were determined by measuring peak systolic velocity (PSV), end-diastolic velocity (EDV) and resistivity index (RI) of the left and right cavernous arteries after an intracavernous injection with prostaglandin E 1 19 and Sexual Encounter Profile (SEP) diary questions 2 and 3. Patient and partner satisfaction was evaluated using the patient version of the Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) questionnaire, a validated 11-item instrument to determine ED treatment satisfaction, with a final score ranging from 0 (extremely low) to 100 (extremely high). 20 
Treatment protocol
All patients were given an instruction sheet prior to randomization, which stressed the timing of medication administration (45 min to 1 h before sexual stimulation) and also the absolute need for sufficient sexual stimulation. Additionally, the instruction sheet emphasized that medication should be taken 2-3 h after a low-fat meal. Following a placebo-lead in phase, patients were randomly divided into two treatment groups using an interactive voice response system, which followed a randomization table generated by the method of randomly permuted blocks. 21 There were 118 patients in sildenafil group (group 1) and 118 patients in the placebo group (group 2). Group 1 received 100 mg sildenafil 1 h before planned sexual activity and group 2 received similar regimen of placebo. The placebo tablet was a starch compound with the same color and size of the sildenafil citrate. Study medications were overencapsulated so that sildenafil and placebo appeared the same. Placebo was prepared by our pharmacy.
Patients were instructed to use at least 24 doses/ attempts at home, but not to have more than one attempt per day. Patients and investigators were blinded with respect to the original treatment assignment. The sildenafil and placebo groups were age matched. Enrolled subjects agreed not to use another form of ED treatment during the entire study period. Dose of levodopa was held constant throughout the study. The use of nitrates in any form was prohibited during the whole study period. Therapy adherence was assessed by direct questioning and pill counts when bottles of study medication were collected.
Efficacy assessments
Patients were screened 6 weeks before the start of the trial, with baseline evaluations made 1 day before, and efficacy assessed every four attempts and at the end of the trial (EOT). All patients were seen with their partners, and interviewed separately about sexual activity and patient EF.
The designated primary outcome measures were (1) the changes in IIEF EF domain score, (2) responses to the questions from the IIEF: question 3, 'When you attempted sexual intercourse, how often were able to penetrate your partner?' and question 4, 'During sexual intercourse, how often were able to maintain your erection to completion of intercourse?' and (3) SEP diary questions 2 ('Were you able to insert your penis into your partner's vagina?') and 3 ('Did your erection last long enough for you to have successful intercourse?').
The five secondary outcome measures included (1) remaining four IIEF domains, (2) responses to a Global Efficacy Question 'Has the treatment you have been taking over the study period improved your erections?', (3) treatment satisfaction as asses-
sed using patient and partner versions of the Inventory of Treatment Satisfaction (EDITS) questionnaire, (4) mean intercourse frequency and (5) and QOL 22 assessment.
Safety assessments
Treatment emergent adverse events (TEAEs) were defined as any AE that first occurred or worsened after the beginning of the study. Safety and tolerability were evaluated on the basis of spontaneously reported adverse effects, physical examination, laboratory analyses and 12-lead electrocardiogram during each patient's visit. Subjects voluntarily reported AEs during the whole study period. Patient reported AEs were assigned by the investigator (M.R.S.) according to the Medical Dictionary for Regulatory Activities low-level terms and summarized at the preferred term in version 7.0.
Statistical analysis
The values were presented as the mean ± s.d., and all analyses were performed using the SPSS 16.0 software for Windows (Chicago, IL, USA). Accepting a level of significance of 5%, to provide a power of 80%, to detect a 10% increase in the IIEF EF domain score, a sample size of 100 patients per arm was necessary. Therefore, assuming an overall 15% dropout rate, 230 patients would be required. Primary and secondary analyses were performed on an intention-to-treat basis and included all randomized patients who received at least one dose of study medication and who returned for at least one post-baseline efficacy follow-up. A 'last observation carried forward' algorithm was applied for any missing post-baseline data. Analysis of covariance was used to assess the primary efficacy measures and all secondary end points except the Global Assessment Question. Logistic regression analysis was used to determine treatment group differences for Global Assessment Question responses. Spearman correlation analysis was used to assess the significance of the relationship between the improvement in EF and measured variables. Fisher's exact tests were conducted to analyze the between group comparisons of TEAEs frequencies.
Results
Patient disposition/demographics
Clinical and demographic data of participants with ED are presented in Tables 1 and 2 . No significant differences were found regarding age, education level, Hoehn-Yahr stages, occupational and marital status, ED severity or baseline IIEF domain scores between the two groups (P ¼ not significant for each). The median time to consume the 24 doses was 88 days for sildenafil (1.9±0.3 dose per week) and 140 days for placebo (1.2 ± 0.3 dose per week) (P ¼ 0.001). Thirty-one patients discontinued the study. The reasons for discontinuation are depicted in Figure 1 .
Treatment efficacy Primary efficacy measures. IIEF-EF domain:
At baseline, mean IIEF EF domain scores ranged between 11 and 15, consistent with moderate ED in both the groups. The overall mean IIEF EF score improved from 12.2 ± 4.2 at baseline to 22.6 ± 4.6 for patients taking sildenafil (P ¼ 0.01) and from 12.6±4.4 at baseline to 14.8±4.2 for patients taking (Table 3) . IIEF questions 3 and 4: At the EOT, the analysis of responses to IIEF question 3 showed a significant (P ¼ 0.01) improvement in the ability to achieve an erection for patients receiving sildenafil compared with those receiving placebo. Mean end point scores were 3.7±0.1 and 1.6±0.2 for patients taking sildenafil and placebo, respectively. The analysis of responses to IIEF question 4 at the EOT also revealed a significant (P ¼ 0.01) treatment effect for the ability to maintain an erection. Mean end point scores were 3.4±0.3 and 1.7±0.2 for patients taking sildenafil and placebo, respectively (Table 3) .
SEP2: During the screening period (week 6), mean per-patient rates of affirmative responses to the SEP2 question were 27.3 ± 2.2% in the sildenafil group and 28.2 ± 2.4% in the placebo group. During the study periods ending after 24 doses/attempts, the mean per patient SEP2 success rate increased to 68.1 ± 4.2% and 32.5 ± 2.2% in the sildenafil and placebo group, respectively (P ¼ 0.003).
SEP3: Sildenafil significantly improved mean perpatient success rates for SEP3 vs placebo (P ¼ 0.004). The mean per-patient success rates in the sildenafil group were 28.6±1.6% at baseline, and 75.9±5.4% at the EOT, compared to placebo with a baseline value of 28.2 ± 1.7%, and 33.5 ± 4.4%, at EOT.
Secondary efficacy measures.
Patients treated with sildenafil also experienced statistically significant clinical benefits over placebo on all secondary efficacy outcome measures.
IIEF domains other than EF: For sildenafil vs placebo, IIEF domain scores were similar at baseline (Table 1) , but sildenafil therapy resulted in significantly higher end point IIEF scores across all other four IIEF domains: orgasmic function, sexual desire, intercourse satisfaction and overall satisfaction, when compared with placebo ( Table 4 ). The greatest Figure 1 Flowchart of recruited subjects.
percentage improvements with sildenafil treatment were in the EF (P ¼ 0.001) and intercourse satisfaction domains (P ¼ 0.001) (Figure 2 ). Global Assessment Question: At the fourth attempt, 68% of men receiving sildenafil and 12% receiving placebo had improved erections. Efficacy was sustained through the study period and was significantly superior to placebo (P ¼ 0.001) at all follow-up points.
EDITS: When comparing the sildenafil group vs placebo, we determined significant differences in the total score of the EDITS. Sildenafil-treated patients had a median EDITS score of 74.6±12.8, which was significantly higher than the median score of 30.6 ± 4.4 for placebo patients (P ¼ 0.001). Overall, the proportion of patients satisfied with treatment (defined as final EDITS score 450) 23 was 70% for the sildenafil-treated group and 13% for the placebo-treated group (P ¼ 0.001) ( Table 3) . Patients treated with sildenafil also experienced statistically significant clinical benefits over placebo on the mean EDITS for partners (Table 5 , P ¼ 0.01) and individual EDITS questions, including overall satisfaction (P ¼ 0.01), partner satisfaction (P ¼ 0.01) and likelihood of continuing treatment (P ¼ 0.01).
Intercourse frequency: After four attempts on toward, mean changes from baseline in the average weekly number of sexual attempts were higher in sildenafil group than placebo group. At the EOT, the mean sexual attempts per week was 1.9 ± 0.3, and 1.2 ± 0.3, in sildenafil and placebo groups, respectively. QOL: Mean QOL scores were comparable between groups at baseline (1.7 ± 0.8 vs 1.7 ± 0.7). Sildenafil group showed significantly superior (3.1 ± 1.4) improvement in QOL over placebo (1.6±0.6) at EOT (P ¼ 0.01). A successful intercourse attempt occurred at least 50% of the time in 72% of sildenafil-treated men vs 16% of placebo-treated men (P ¼ 0.001).
Secondary analysis. For patients having mild ED (EF domain scores of 22-25), 72 and 12% of
Percentage changes from baseline in IIEF questions 3 and 4, and SEP2 and SEP3 scores, are shown in Figure 3 . The differences between the two groups were statistically significant (Po0.01).
Correlation coefficients calculated between IIEF domains and EDITS scores showed that the IIEF overall satisfaction, and intercourse satisfaction domain scores had the highest correlations with the EDITS (r ¼ 0:74, P ¼ 0.001 and r ¼ 0.81, P ¼ 0.001; respectively). Correlations between EDITS and EF (r ¼ 0:65, P ¼ 0.01), sexual desire (r ¼ 0:61, P ¼ 0.01) and orgasmic function (r ¼ 0.52, P ¼ 0.02) domains were lower. Subgroup analysis based on disease stage showed significant difference between them. Patients with stage I disease had a higher percentage of increases in the primary and secondary efficacy measures, compared with placebo patients with stage III disease (Table 6; Figure 4 ). After adjusting age due to its influence on EF, correlation analysis revealed that the improvement in EF had strong negative correlation with disease stage (r ¼ À0.84, P ¼ 0.001). A positive and statistically strong correlation exists between the severity of ED and degree of disease stage (r ¼ 0.72, P ¼ 0.001).
Adverse events. Adverse events occurring in X5% of either groups are shown in Table 7 . Sildenafil was generally well tolerated, and TEAEs were mostly mild and transient. Thirty-nine percent of sildenafil patients and 6% of placebo patients experienced at 
least one TEAEs (P ¼ 0.002); however, a small proportion of participants withdrew (3.4 vs 0.8%, P ¼ 0.07). Four patients (3.4%) in the sildenafil group (two for headache, one for hot flashes and one for dyspepsia) and one patient (0.8%) in the placebo group (for headache) withdrew because of TEAEs. There were no drug-related serious AEs.
Discussion
Compared with placebo, on demand sildenafil improved EF and sexual satisfaction secondary to PD, as measured by improvement in IIEF EF domain and EDITS. The primary efficacy measure, IIEF EF domain, demonstrated an overall 85% and 17% improvement in the sildenafil and placebo groups, respectively. Moreover, improvements in EF correlated positively with improvements in QOL, which may imply a high level of satisfaction with treatment in PD patients successfully treated with sildenafil for ED.
Results from this study agree with previous openlabel study. 9 The cited open-label study suffered from small sample size. In addition, all of the Figure 3 The percentage change from baseline in International Index of Erectile Function (IIEF) domains at the end of the study. recruited patients were depressed, and patients with all types of ED (including vasculogenic) have been recruited. Although the complex sexual dysfunction is one of the most disabling non-motor symptoms in patients suffering from PD, 24 it has been widely ignored. In PD, the estimates for ED are between 60 and 80%. 25, 26 Although ED is common in PD, the development of hypersexuality and aberrant sexual behavior, probably due to dopamine replacement therapy has also been reported. In 0.9% of patients, treatment with L-Dopa leads to hypersexuality. 27 Similarly, in another study, use of a dopamine agonist was associated with compulsive sexual behavior in 2.7% of PD patients. 28 Hypersexuality may be considered as an increase in libido as opposed to a result of frontal lobe disinhibition. 29 Men with PD, and their partners, have more marital and sexual problems than women with PD, and their partners. 30 With the advent of oral drugs for the treatment of ED and improvements in living standards, interest in sexual function is increasing; but, few studies have addressed the sexual lives of PD patients. Question about sexual functioning may be overlooked by neurologists due to time limitations, embarrassment about sexual conversation and lack of proper training. This issue should be raised by clinicians at an early stage, and this needs to become a standard practice.
The changes in sexual health of patients with PD must be a concern to the physicians. Although understanding of the central and peripheral physiology of sexual function has grown considerably over the last decade, our knowledge of the neuronal circuits involved in sexual response remains incomplete. The advent of functional brain imaging has, led to the determining of several areas of the brain implicated in sexual arousal. Of note, autopsybased investigations have demonstrated the existence of PD-related lesions in these areas. 31 In patients with PD, impairment of autonomic nervous system controlling EF, physical limitations and emotional changes are also contributory factors for developing psychogenic and neurogenic ED.
Owing to the aim of the study, patients with endocrinologic, vasculogenic and psychogenic ED, and patients with more advanced disease stage were excluded. It should be also emphasized that, in this study, men were also excluded if they had associated conditions, such as diabetes mellitus, hyperlipidemia, spinal cord injury, depression, radical prostatectomy or endocrinopathy such as low testosterone or thyroid-stimulating hormonal levels. We had to do this for recruitment of patients with Parkinson-emergent ED.
The efficacy of sildenafil for ED in different circumstances and in a myriad of pathological conditions is well known; however, in certain associated conditions with ED, such as diabetes mellitus, 32, 33 multiple sclerosis 34 and post-traumatic stress disorder, 35 sildenafil has little or no effect. In a pooled analysis of flexible-dose, placebo-controlled, double-blind studies of sildenafil, 36 men with ED preferred the increased efficacy of the maximal dose of drug. In addition, due to placebo-controlled nature of the study, a dose-escalating design was not pragmatic. Therefore, we used the dose of 100 mg in all patients. All of the participants were free from the cardiovascular diseases, and AEs and vital signs were closely monitored in all patients throughout the whole treatment period. Raffaele et al. studied the efficacy of sildenafil 50 mg in 33 depressed men with PD and ED. The reported improvement rate in EF was 84.4%. 9 The overall success rate with 100 mg sildenafil in our study was 65%. The overall positive response rate to sildenafil in the general population is between 65 and 75%. 37 It is difficult to explain such a dramatic difference between efficacy rates, but several factors contribute to these discrepancies. There are substantial differences in patient selection criteria. In the study by Raffaele et al., participants had ED associated with PD, not PD-related ED. The studies also had differing methodologies, and the diversity of response to sildenafil may reflect individual variation in PD.
In the present study, sildenafil 100 mg on demand, demonstrated significant efficacy over placebo on measures of EF, overall satisfaction, erection hardness and partner satisfaction in Parkinson-affected men with ED. Furthermore, the change was clinically meaningful. Of note, 57.0 and 10% of patients receiving sildenafil and placebo attained IIEF EF domain scores X26, representing no ED, at EOT (P ¼ 0.001). In addition, 68% of post-baseline sexual intercourse attempts were successful for patients taking sildenafil compared with 32% for placebotreated patients (P ¼ 0.003).
Sildenafil is widely available in Iran. Unfortunately, in some circumstances it is widely available without prescription too. The most appropriate therapy for ED in a particular condition depends on the specific diagnosis. All of our subjects had intact blood supply 
to corpora cavernosal. Sildenafil citrate, selectively inhibits cyclic guanosine monophosphate-specific PDE type 5, leading to increased cyclic guanosine monophosphate levels, which result in muscle relaxation and increased blood flow to corpora cavernosal. Sildenafil efficacy significantly decreases in men with severe vasculogenic ED. 38 If the blood flow study indicates severe arterial insufficiency, sildenafil is not likely to treat ED. Indeed PD does not compromise penile vasculature. Namely, Parkinson-emergent ED will not be vasculogenic. In this study, the response to sildenafil was highly dependent on the severity of ED and disease stage. When the treatment groups were subdivided according to the severity of ED, an improvement in IIEF EF domain score was evident in all subgroups. However, rigidity sufficient for satisfactory sexual intercourse was reported by 32% of patients with severe ED and 78% with mild ED. Most of the men in this study had moderate or severe ED. It is of note that a major difference was seen between the different disease stages. Our study demonstrates that 76% of patients with stage I Parkinson responded to sildenafil as compared with 42% of patients with stage III disease.
Overall, the results of this study demonstrate that sildenafil is an effective and well-tolerated therapy in PD patients with ED. AEs occurred more frequently with sildenafil than with placebo. The most common AEs seen were typical of PDE5 inhibitors (for example headache, hot flashes) and were of mild-to-moderate in nature. The AE profiles are similar to Raffaele et al. 9 in spite of use of larger dose in this study. We could not fully explain this issue. However, most common AEs associated with sildenafil (headache, flashing, nausea and colorvision disturbance) are subjective symptoms. Reporting a symptom depends on how distressing patients found a symptom. In addition, the type of disease for which patients are being treated might influence the reported rate of AEs. Raffaele et al. ' s study has been conducted in PD patients with depression.
Additionally, patients and partners in our series reported significant improvement in QOL after sildenafil treatment. It could be interesting to perform a similar study in patients under different treatment (other than levodopa) or in patients who are receiving multiple treatments for PD, to see if there is a difference in ED improvement. Placebo effect is a known phenomenon in pharmacotherapy for ED. In the present study, we excluded the placebo-responders in placebo-lead in phase. In clinical trials without controls, one must keep this effect and its relative size in mind, and interpret the data from such studies with appropriate caution.
This study has limitations. The fact that patients in this study were excluded if they had an associated risk factor or comorbidity might have contributed to the favorable results. In addition, this study investigated fixed-dose sildenafil 100 mg and disallowed dose reductions due to poor tolerability. We did not evaluate the lower urinary tract symptoms. They were not excluded.
Conclusion
Sildenafil citrate is an effective treatment for ED in patients with PD. Although more advanced disease stage, and severity of ED negatively affect the efficacy of sildenafil, still, the global efficacy and the overall patient's and partner's satisfaction were high.
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